ANIMAL PHARMACOKINETICS OF FK037, A NOVEL PARENTERAL BROAD-SPECTRUM CEPHALOSPORIN

被引:17
作者
SAKAMOTO, H
HATANO, K
HIGASHI, Y
MINE, Y
NAKAMOTO, S
TAWARA, S
KAMIMURA, T
MATSUMOTO, F
KUWAHARA, S
机构
[1] FUJISAWA PHARMACEUT CO LTD,NEW DRUG RES LABS,OSAKA 532,JAPAN
[2] KANAGAWA PREFECTURAL NURSING & HYG SCH HOSP,YOKOHAMA,JAPAN
[3] TOHO UNIV,SCH MED,TOKYO 143,JAPAN
关键词
D O I
10.7164/antibiotics.46.120
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Single-dose pharmacokinetics of FK037 has been investigated in laboratory animals. After bolus intravenous dosing with 20 mg/kg, the elimination half-life of FK037 varied in the species; with values of 0.27, 0.30, 0.97, 1.29 and 1.76 hours in mice, rats, rabbits, dogs and monkeys, respectively. The volume of distribution ranged between 260 ml/kg in rats and 390 ml/kg in dogs. These parameters approximated those of ceftazidime and cefpirome used as reference drugs. The renal clearance of FK037 was almost equal to-glomerular filtration rate (GFR) in rabbits. Probenecid did not affect the elimination half-life of FK037 and its clearance ratio to GFR. These findings suggest that FK037 is solely excreted by glomerular filtration. FK037 readily penetrated into the tissues and inflammatory exudate fluid in rats, and the tissue level was highest in the kidneys, and decreased in the following order; lungs > heart > liver > spleen. Penetration of FK037, cefpirome and ceftazidime into the cerebrospinal fluid were determined using induced staphylococcal meningitis in rabbits. The penetration percentage ranged from 14.2 to 16.0% for these drugs with no significant differences. The major route of excretion of FK037 was via the kidney, with more than 74% of the dose being excreted in the urine within 24 hours after dosing to each species. Biliary excretion was low, 0.79% in rats. Bioautograms showed only unchanged drug in the plasma, urine and bile. Serum protein binding was low (8.8 to 17.6%) in all the species studied.
引用
收藏
页码:120 / 130
页数:11
相关论文
共 13 条
[1]   THERAPEUTIC AND KINETIC-PROPERTIES OF CEFTAZIDIME IN ANIMALS [J].
ACRED, P .
INFECTION, 1983, 11 :S44-S48
[2]   CHEMICAL MEASUREMENTS OF INULIN CONCENTRATIONS IN PERITONEAL-DIALYSIS SOLUTION [J].
BROWN, P ;
NOLPH, KD .
CLINICA CHIMICA ACTA, 1977, 76 (01) :103-112
[3]   RENAL DISPOSITION OF CEFTAZIDIME ILLUSTRATED BY INTERFERENCES BY PROBENECID, FUROSEMIDE, AND INDOMETHACIN IN RABBITS [J].
CARBON, C ;
DROMER, F ;
BRION, N ;
CREMIEUX, AC ;
CONTREPOIS, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (03) :373-377
[4]   PHARMACOKINETIC PROPERTIES OF THE NEW CEPHALOSPORIN ANTIBIOTIC HR-8-10 IN ANIMALS [J].
KLESEL, N ;
SEEGER, K .
INFECTION, 1983, 11 (06) :318-321
[5]  
KOBAYASHI IY, 1983, CHEMOTHERAPY S3, V31, P125
[6]   COMPARATIVE MULTIPLE-DOSE PHARMACOKINETICS OF CEFOTAXIME, MOXALACTAM, AND CEFTAZIDIME [J].
LUTHY, R ;
BLASER, J ;
BONETTI, A ;
SIMMEN, H ;
WISE, R ;
SIEGENTHALER, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1981, 20 (05) :567-575
[7]   EXCELLENT ACTIVITY OF FK037, A NOVEL PARENTERAL BROAD-SPECTRUM CEPHALOSPORIN, AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCI [J].
MINE, Y ;
WATANABE, Y ;
SAKAMOTO, H ;
HATANO, K ;
KUNO, K ;
KAMIMURA, T ;
TAWARA, S ;
MATSUMOTO, Y ;
MATSUMOTO, F ;
KUWAHARA, S .
JOURNAL OF ANTIBIOTICS, 1993, 46 (01) :99-119
[8]   INVIVO ANTIBACTERIAL ACTIVITY OF FK037, A NOVEL PARENTERAL BROAD-SPECTRUM CEPHALOSPORIN [J].
MINE, Y ;
WATANABE, Y ;
SAKAMOTO, H ;
HATANO, K ;
WAKAI, Y ;
KAMIMURA, T ;
TAWARA, S ;
MATSUMOTO, S ;
MATSUMOTO, F ;
KUWAHARA, S .
JOURNAL OF ANTIBIOTICS, 1993, 46 (01) :88-98
[9]  
MINE Y, 1993, J ANTIBIOT, V46, P71, DOI 10.7164/antibiotics.46.71
[10]   PHARMACOKINETICS OF CEFTIZOXIME IN ANIMALS AFTER PARENTERAL DOSING [J].
MURAKAWA, T ;
SAKAMOTO, H ;
FUKADA, S ;
NAKAMOTO, S ;
HIROSE, T ;
ITOH, N ;
NISHIDA, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 17 (02) :157-164